Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test may spot pre-eclampsia risk early in pregnancy

NCT ID NCT01490489

Diagnosis Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a protein called EG-VEGF in the blood of pregnant women could predict pre-eclampsia or poor fetal growth. Researchers took blood samples and performed ultrasound scans on 142 women early in pregnancy. The goal was to see if EG-VEGF levels could serve as an early warning sign for these serious conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to identify pregnant women at risk for pre-eclampsia or fetal growth problems early on.
What could go wrong
This is an observational study, not a treatment trial. It only measures a potential marker; even if the marker is linked, it may not be accurate enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

142 people

The number who actually took part.

Started

Jul 2011

Finished

Mar 2015

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women older than 17 years old * All pregnant patients enrolled before 14 SG and with singleton, irrespectively of their parity * Pregnant woman living in the Grenoble area * Women accepting, the participation to the study. Exclusion Criteria: * Inability to understand the project * Persons deprived of their liberty by judicial or administrative decisions * Person under legal protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intra-uterine growth retardation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fetal growth restriction preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intra-uterine growth retardation Pre-eclampsia

Contacts and locations

Locations

  • Clinical investigation center of the Grenoble University Hospital

    Grenoble, Isere, 38043, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.